Combination therapy for the treatment of estrogen-sensitive disease
US5550107A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Nov 4, 1991 |
| Grant date | Aug 27, 1996 |
| Priority date | — |
| Expiry date | Nov 4, 2011 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treatment of breast and endometrial cancer in susceptible warm-blooded animals may include inhibition of ovarian hormonal secretion by surgical (ovariectomy) or chemical (use of an LHRH agonist, e.g. [D-Trp.sup.6, des-Gly-NH.sub.2.sup.10 ]LHRH ethylamide or antagonist) as part of a combination therapy comprising administering an antiestrogen together with at least one compound selected from the group consisting of an androgen, a progestin, at least one inhibitor of sex steroid formation, especially 17.beta.-hydroxysteroid dehydrogenase and aromatase activity, at least one inhibitor of prolactin secretion, one inhibitor of growth hormone secretion and one inhibitor of ACTH secretion. Pharmaceutical compositions useful for such treatment and pharmaceutical kits containing such composition are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.